Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion type Assertion NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_head.
- NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion description "[Encouraging preclinical results with ado-trastuzumab emtansine (T-DM1) exemplifies a new potential treatment for HER2-positive BCa along with innovative bispecific antibodies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_provenance.
- NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion evidence source_evidence_literature NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_provenance.
- NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion SIO_000772 25498841 NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_provenance.
- NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion wasDerivedFrom befree-2016 NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_provenance.
- NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_assertion wasGeneratedBy ECO_0000203 NP1247104.RAOw7T8JhwAIDRHPrRiF6Br3ou0UFTQzV2X-IuWTmAbWQ130_provenance.